Kim SH, Kwon WA, Joung JY, Seo HK, Lee KH, Chung J. Clear cell papillary renal cell carcinoma: A case report and review of the literature. World J Nephrol 2018; 7(8): 155-160 [PMID: 30596034 DOI: 10.5527/wjn.v7.i8.155]
Corresponding Author of This Article
Jinsoo Chung, MD, PhD, Doctor, Department of Urology, Center for Prostate Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Goyang 410-769, South Korea. cjs5225@ncc.re.kr
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Nephrol. Dec 17, 2018; 7(8): 155-160 Published online Dec 17, 2018. doi: 10.5527/wjn.v7.i8.155
Clear cell papillary renal cell carcinoma: A case report and review of the literature
Sung Han Kim, Whi-An Kwon, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Sung Han Kim, Whi-An Kwon, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung, Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang 410-769, South Korea
Author contributions: Chung J, Kwon WA and Kim SH conceived of the study, participated in its design and coordination, and helped to draft the manuscript; Chung J and Kwon WA performed the surgery; Kim SH wrote the manuscript; all authors read and approved the final manuscript.
Informed consent statement: The patient provided written informed consent for the publication of this case report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no competing interests or relevant financial relationships with either individuals or organizations.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author to: Jinsoo Chung, MD, PhD, Doctor, Department of Urology, Center for Prostate Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Goyang 410-769, South Korea. cjs5225@ncc.re.kr
Telephone: +82-31-9201676 Fax: +82-31-9201790
Received: August 2, 2018 Peer-review started: August 3, 2018 First decision: August 21, 2018 Revised: October 29, 2018 Accepted: November 8, 2018 Article in press: November 8, 2018 Published online: December 17, 2018 Processing time: 137 Days and 18.9 Hours
ARTICLE HIGHLIGHTS
Case characteristics
The patient was referred to the urology department for a right-sided renal mass (size: 2 cm) detected during routine annual imaging follow-up for a malignant right inguinal fibrous histocytoma and liposarcoma that had been diagnosed 6 and 4 years earlier, respectively.
Clinical diagnosis
A routine computed tomography (CT) scan detected a right-sided enhancing mid-pole renal mass measuring 2.3.
Differential diagnosis
Immunohistochemistry revealed carbonic anhydrase 9 (CA9) expression could be helpful for differential diagnosis.
Imaging diagnosis
A routine CT scan detected a right-sided enhancing mid-pole renal mass measuring 2.3 cm.
Pathological diagnosis
pathology revealed a tumor measuring 1.7 cm × 1.4 cm × 1.0 cm with a capsule abutting, leading to a diagnosis of a grade 2 ccpRCC without necrosis and a final pathologic stage of T1aN × M0.
Treatment
The patient underwent open right-sided partial nephrectomy.
Experiences and lessons
Patients who have previously been treated with tumor need careful follow-up.
